期刊
REGULATORY TOXICOLOGY AND PHARMACOLOGY
卷 67, 期 1, 页码 89-97出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.yrtph.2013.07.002
关键词
Dapagliflozin; Occupational exposure limit; Pharmacokinetics; SGLT2 inhibitors; Urinary glucose excretion
资金
- Bristol-Myers Squibb Co.
- AstraZeneca
Classical risk assessment models for setting safe occupational exposure limits (OEL) have used multiple uncertainty factors (UF) applied to a point of departure (POD), e.g., a No Observed Effect Level (NOEL), which in some cases is the pharmacological effect. Dapagliflozin promotes glucosuria by inhibiting the renal sodium-glucose cotransporter-2 transporter. The initial OEL for dapagliflozin (0.002 mg/m(3)) was calculated when low dose clinical data was not available to identify a NOEL resulting in the need to use excessive UFs. To reduce the UFs from the OEL, a clinical pharmacodynamic [glucosuria and urinary glucose dipstick (UGD)] and pharmacokinetic study was conducted with single oral doses of 0.001, 0.01, 0.1, 0.3, 1.0 or 2.5 mg administered to 36 healthy subjects. Dose-related dapagliflozin systemic exposures were observed at doses >= 0.1 mg and glucosuria was observed at doses >= 0.3 mg and corroborated by UGD. The NOEL was therefore 0.1 mg for glucosuria. For setting the new OEL, no UFs were required. Dividing the POD by 10 m(3) (the volume of air an adult inhales in a workday), the resulting OEL was 0.01 mg/m(3). In conclusion, low-dose clinical pharmacodynamic and pharmacokinetic data can allow the OEL to be adjusted to the highest safe level. (C) 2013 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据